Posts

Celldex drops eczema program after Phase 2 trial misses endpoints

Celldex Therapeutics is discontinuing development of barzolvolimab for moderate-to-severe atopic dermatitis (eczema) after its Phase 2 study failed to meet the primary itch endpoint or key secondary measures. The study enrolled 131 patients. At Week 16, itch scores fell 29.2% with the 300 mg dose and 16.2% with the 150 mg dose, compared with 19.5% on placebo; neither dose showed a statistically significant advantage over placebo. Measures of eczema severity and skin clearance also did not meaningfully separate from placebo, and extending treatment to Week 32 did not produce added improvement. Celldex said the results fell short of its internal threshold for continued development. The drug was well tolerated, and the company said the data suggest mast cells may contribute to eczema but are not a primary driver. The setback is specific to eczema; Celldex continues to develop barzolvolimab for chronic hives and other indications. Sources: Celldex Reports Results from Phase 2 S...

Merck reports Phase 3 survival win for sac-TMT in advanced gastroesophageal cancer

Congress is split over Treasury’s proposed China biotech investment rules

Sanofi–Insmed: clear respiratory fit, but no deal confirmed

Experimental malaria vaccine protects 13 of 15 volunteers in early trial

MegaRobo raises nearly $200M

SELLAS AML vaccine posts Phase III survival benefit—promising, but not yet an approval

Commure acquires Elaborate to automate clinicians’ inbox work

Regeneron enters neurology with FDA approval of Livsayis for myasthenia gravis

FDA approves Sanofi’s Infilbray as first treatment for Type 3 Gaucher neurological symptoms

AbbVie and DISCO strike solid-tumor research deal worth up to $2.54B

nChroma halts hepatitis B trial and cuts workforce by about half

Jefferies biotech dispatch: AI, PI3Kα and protein degraders